NCT05941169View on ClinicalTrials.gov

Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy

NANot yet recruitingINTERVENTIONAL

Enrollment

750

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

April 1, 2030

Study Completion Date

April 1, 2031

Conditions

Renal Cell Carcinoma

Interventions

PROCEDURE

Cytoreductive Nephrectomy

The experimental intervention consists of cytoreductive nephrectomy (CN) or any ablative local therapy within 6 months and 1 year after start of systemic treatment. All types of ablative local therapy are allowed as a substitute for CN

All Listed Sponsors

collaborator

Comprehensive Cancer Centre The Netherlands

OTHER

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT05941169 - Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy | Biotech Hunter | Biotech Hunter